Atomwise vs Schrödinger
Predict the binding or simulate it, and both companies have published enough that the argument can be had on evidence rather than on claims. Atomwise built a deep convolutional network that predicts small molecule bioactivity in three dimensions and uses it to screen ultra large synthesizable libraries in place of physical high throughput screening, and it did the thing almost nobody in this category does: published the denominator, reporting how many model selected compounds were tested and how many held up. Schrodinger simulates the physics, with a larger and older independently benchmarked literature, coverage across the discovery chain and a molecule in late stage development. For a chemistry team the real question is whether your targets have the structural data physics based methods need, because where they do the simulation is the more defensible answer and where they do not, screening is the only one available.
- The method is in the peer reviewed literature rather than in marketing copy, with the core screening result published and the network patented and described rather than referred to as proprietary.
- It reports its own denominator. The screening programme published how many predictions were tested and how many held up, which is the disclosure this category almost never makes and the reason its evidence grade is the strongest here.
- Virtual screening against an ultra large synthesizable library replaces physical high throughput screening, which is a specific and measurable substitution rather than a general claim about acceleration.
- The published and independently benchmarked method literature is larger and older, and the platform spans the discovery chain rather than one screening step.
- Evidence exists at asset level as well as platform level, including a molecule from the platform in late stage development.
- It is licensed software with the broadest coverage in this category, usable in house across small molecule discovery and adjacent domains rather than accessed through a discovery collaboration.
Side by Side
| Axis | A Atomwise |
S Schrödinger |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
The two run on different mechanisms and should not be compared on accuracy: one is a deep convolutional network predicting bioactivity from structure, the other is physics based simulation, and Schrodinger's low AI centrality grade reflects that rather than any judgement of quality. Neither holds a located SOC 2, ISO 27001 or equivalent attestation.
Atomwise's strongest evidence is a platform level screening result rather than a clinical outcome, and no molecule from either company should be treated as evidence that the platform generalises beyond the targets already published.